Ftse Mib
34.171,37
-0,36%
DAX
18.042,01
-0,50%
S&P 500
5.116,17
0,32%
NASDAQ Composite
15.983,08
0,00%
Bitcoin
61.255,90
-4,04%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ovid Therapeutics Inc (OVID) Ovid Therapeutics Inc (OVID) Notizie

Ovid Therapeutics Inc

OVID
3,34
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:04:09
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
04/4/202414:00GLOBEOvid Therapeutics to Present at the 23rd Annual Needham..
08/3/202414:24EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202414:20EDGAR2Form 8-K - Current report
08/3/202414:00GLOBEOvid Therapeutics Reports Business Updates, Fourth Quarter..
28/2/202414:00GLOBEOvid Therapeutics to Present at the TD Cowen 44th Annual..
27/2/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202417:10EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202412:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202414:00GLOBEOvid Therapeutics to Present at the Oppenheimer 34th Annual..
06/12/202323:08EDGAR2Form 8-K - Current report
01/12/202313:30GLOBEOvid Therapeutics to Present Five Abstracts Supporting its..
16/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
15/11/202322:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/11/202321:08EDGAR2Form S-3 - Registration statement under Securities Act of..
03/11/202313:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202313:10EDGAR2Form 8-K - Current report
03/11/202313:00GLOBEOvid Therapeutics Reports Third Quarter 2023 Financial..
18/10/202314:04EDGAR2Form 8-K - Current report
18/10/202314:00GLOBEOvid Therapeutics and Ligand Pharmaceuticals Enter into a..
10/10/202314:00GLOBEOvid Therapeutics to Present at the Jefferies Biotech..
02/10/202318:15EDGAR2Form 8-K - Current report
26/9/202313:30GLOBEOvid Therapeutics to Host Investor Event - R&D Day on..
20/9/202313:30GLOBEOvid Therapeutics to Present at the 2023 Cantor Fitzgerald..
30/8/202314:00GLOBEOvid Therapeutics to Participate in Upcoming September..
04/8/202315:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202315:10EDGAR2Form 8-K - Current report
04/8/202314:00GLOBEOvid Therapeutics Reports Second Quarter 2023 Financial..
01/8/202314:00GLOBEOvid Therapeutics to Present at the BTIG Virtual..
31/7/202323:21EDGAR2Form SC 13G - Statement of acquisition of beneficial..
28/6/202314:00GLOBEOvid Therapeutics Expands Its Scientific Leadership Team &..
26/6/202314:00GLOBEOvid Therapeutics Added to Russell 3000® Index
05/5/202313:30GLOBEOvid Therapeutics Reports First Quarter 2023 Financial..
01/5/202312:00GLOBEOvid Therapeutics Announces Collaboration with Graviton..
Apertura: Min: Max:
Chiusura: 3,34

La tua Cronologia

NASDAQ
OVID
Ovid Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network